Study in healthy males to assess the bioavailability of 4 different fostamatinib tablets

Study identifier:D4300C00018

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

An open-label, partially randomized, 5-way crossover study in healthy volunteers to assess the relative bioavailability of 100 and 150 mg fostamatinib tablets compared with 50 mg fostamatinib tablets

Medical condition

Healthy

Phase

Phase 1

Healthy volunteers

Yes

Study drug

Fostamatinib

Sex

Male

Actual Enrollment

24

Study type

Interventional

Age

18 Years - 55 Years

Date

Study Start Date: 01 Aug 2011
Primary Completion Date: 01 Oct 2011
Study Completion Date: 01 Oct 2011

Study design

Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Basic Science

Verification:

Verified 01 Jan 2014 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria